发布求助
文献互助 智能选刊 最新文献

Drug Discovery Today最新文献

筛选
英文 中文
Spotlight on HIV-derived TAT peptide as a molecular shuttle in drug delivery 聚焦作为药物输送分子穿梭器的艾滋病毒衍生 TAT 肽。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-24 DOI: 10.1016/j.drudis.2024.104191
Zahra Maani , Leila Rahbarnia , Ali Bahadori , Khalil Maleki Chollou , Safar Farajnia
{"title":"Spotlight on HIV-derived TAT peptide as a molecular shuttle in drug delivery","authors":"Zahra Maani ,&nbsp;Leila Rahbarnia ,&nbsp;Ali Bahadori ,&nbsp;Khalil Maleki Chollou ,&nbsp;Safar Farajnia","doi":"10.1016/j.drudis.2024.104191","DOIUrl":"10.1016/j.drudis.2024.104191","url":null,"abstract":"<div><div>HIV-derived TAT peptide, with a high penetration rate into cells and its nonimmunogenic and minimally toxic nature, is an attractive tool for enhancing the biodistribution of drugs and their systemic administration. Despite the presence of numerous promising preclinical investigations illustrating its capability to specifically target distinct tissues and deliver a diverse range of pharmacological agents, the efficacy of various clinical trials incorporating TAT has been impeded by several considerable obstacles. Hence, there is much need for an in-depth investigation concerning the application of TAT in drug delivery mechanisms. In this review, we have elucidated the structure of TAT and its utility in the proficient delivery of various types of bioactive molecules.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104191"},"PeriodicalIF":6.5,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142338159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Downregulation of microRNA-29b in cancer and fibrosis: molecular insights and clinical implications 癌症和纤维化中 microRNA-29b 的下调：分子见解和临床意义。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-24 DOI: 10.1016/j.drudis.2024.104190
Pratik Pramod Shinde, Deepak Chitkara, Anupama Mittal
{"title":"Downregulation of microRNA-29b in cancer and fibrosis: molecular insights and clinical implications","authors":"Pratik Pramod Shinde,&nbsp;Deepak Chitkara,&nbsp;Anupama Mittal","doi":"10.1016/j.drudis.2024.104190","DOIUrl":"10.1016/j.drudis.2024.104190","url":null,"abstract":"<div><div>MicroRNA-29b (miR-29b) is known for its therapeutic potential as an antifibrotic and anticancer agent. In fibrotic conditions, miR-29b inhibits fibrogenesis by downregulating crucial regulators such as collagens, extracellular matrix proteins and the transforming growth factor-β pathway. Similarly, in cancer, it acts as a tumor suppressor by downregulating various oncogenes and signaling pathways involved in cancer progression, such as Wnt–β-catenin, p38–mitogen-activated protein kinase and nuclear factor-κB. However, the upregulation of these pathways suppresses miR-29b, contributing to fibrosis and cancer development. Preclinical research and clinical trials have shown that delivering exogenous miR-29b mimics can restore its expression, attenuating tumorigenesis and fibrogenesis. This review discusses miR-29b’s potential and its possible therapeutic development for cancer and fibrotic disorders.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104190"},"PeriodicalIF":6.5,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142338156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From promise to progress: the dynamic landscape of glioblastoma immunotherapy 从希望到进步：胶质母细胞瘤免疫疗法的动态发展。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-20 DOI: 10.1016/j.drudis.2024.104188
Muhammad Ijaz , Zia Ullah , Bilal Aslam , Mohsin Khurshid , Pengfei Chen , Bing Guo
{"title":"From promise to progress: the dynamic landscape of glioblastoma immunotherapy","authors":"Muhammad Ijaz ,&nbsp;Zia Ullah ,&nbsp;Bilal Aslam ,&nbsp;Mohsin Khurshid ,&nbsp;Pengfei Chen ,&nbsp;Bing Guo","doi":"10.1016/j.drudis.2024.104188","DOIUrl":"10.1016/j.drudis.2024.104188","url":null,"abstract":"<div><div>Glioblastoma multiforme (GBM) is the most common CNS cancer, it has dismal survival rates despite several effective mediators: intensified cytotoxic therapy, chimeric antigen receptor (CAR)-T cell therapy, viral therapy, adoptive cell therapy, immune checkpoint blockade therapy, radiation therapy and vaccine therapy. This review examines the basic concepts underlying immune targeting and examines products such as checkpoint blockade drugs, CAR-T cells, oncolytic viruses, combinatory multimodal immunotherapy and cancer vaccines. New approaches to overcoming current constraints and challenges in GBM therapy are discussed, based on recent studies into these tactics, findings from ongoing clinical trials, as well as previous trial results.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104188"},"PeriodicalIF":6.5,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the macrophage dynamics in osteoarthritic joints: From inflammation to therapeutic strategies 揭示骨关节炎关节中巨噬细胞的动态变化：从炎症到治疗策略。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-19 DOI: 10.1016/j.drudis.2024.104187
Nicolas Gaigeard , Anaïs Cardon , Benoit Le Goff , Jérôme Guicheux , Marie-Astrid Boutet
{"title":"Unveiling the macrophage dynamics in osteoarthritic joints: From inflammation to therapeutic strategies","authors":"Nicolas Gaigeard ,&nbsp;Anaïs Cardon ,&nbsp;Benoit Le Goff ,&nbsp;Jérôme Guicheux ,&nbsp;Marie-Astrid Boutet","doi":"10.1016/j.drudis.2024.104187","DOIUrl":"10.1016/j.drudis.2024.104187","url":null,"abstract":"<div><div>Osteoarthritis (OA) is an incurable, painful, and debilitating joint disease affecting over 500 million people worldwide. The OA joint tissues are infiltrated by various immune cells, particularly macrophages, which are able to induce or perpetuate inflammation. Notably, synovitis and its macrophage component represent a target of interest for developing treatments. In this review, we describe the latest advances in understanding the heterogeneity of macrophage origins, phenotypes, and functions in the OA joint and the effect of current symptomatic therapies on these cells. We then highlight the therapeutic potential of anticytokines/chemokines, nano- and microdrug delivery, and future strategies to modulate macrophage functions in OA.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104187"},"PeriodicalIF":6.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer 抑制 MAT2A 可对抗癌症中的代谢和转录重编程。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-19 DOI: 10.1016/j.drudis.2024.104189
Fadi E. Pulous , Barbara Steurer , Frank W. Pun , Man Zhang , Feng Ren , Alex Zhavoronkov
{"title":"MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer","authors":"Fadi E. Pulous ,&nbsp;Barbara Steurer ,&nbsp;Frank W. Pun ,&nbsp;Man Zhang ,&nbsp;Feng Ren ,&nbsp;Alex Zhavoronkov","doi":"10.1016/j.drudis.2024.104189","DOIUrl":"10.1016/j.drudis.2024.104189","url":null,"abstract":"<div><div>Metabolic and transcriptional reprogramming are crucial hallmarks of carcinogenesis that present exploitable vulnerabilities for the development of targeted anticancer therapies. Through controlling the balance of the cellular methionine (MET) metabolite pool, MET adenosyl transferase 2 alpha (MAT2A) regulates crucial steps during metabolism and the epigenetic control of transcription. The aberrant function of MAT2A has been shown to drive malignant transformation through metabolic addiction, transcriptional rewiring, and immune modulation of the tumor microenvironment (TME). Moreover, MAT2A sustains the survival of 5′-methylthioadenosine phosphorylase (MTAP)-deficient tumors, conferring synthetic lethality to cancers with MTAP loss, a genetic alteration that occurs in ∼15% of all cancers. Thus, the pharmacological inhibition of MAT2A is emerging as a desirable therapeutic strategy to combat tumor growth. Here, we review the latest insights into MAT2A biology, focusing on its roles in both metabolic addiction and gene expression modulation in the TME, outline the current landscape of MAT2A inhibitors, and highlight the most recent clinical developments and opportunities for MAT2A inhibition as a novel anti-tumor therapy.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104189"},"PeriodicalIF":6.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond resmetirom approval for NAFLD: what has to be done? 非酒精性脂肪肝的雷美替罗批准之外：还需要做些什么？
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-19 DOI: 10.1016/j.drudis.2024.104185
Devaraj Ezhilarasan
{"title":"Beyond resmetirom approval for NAFLD: what has to be done?","authors":"Devaraj Ezhilarasan","doi":"10.1016/j.drudis.2024.104185","DOIUrl":"10.1016/j.drudis.2024.104185","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104185"},"PeriodicalIF":6.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies 蛋白质组学在中风和心肌梗塞新药发现和风险预测优化中的应用：人体研究综述。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-19 DOI: 10.1016/j.drudis.2024.104186
Richard J. Webb , Maha Al-Asmakh , Maciej Banach , Mohsen Mazidi
{"title":"Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies","authors":"Richard J. Webb ,&nbsp;Maha Al-Asmakh ,&nbsp;Maciej Banach ,&nbsp;Mohsen Mazidi","doi":"10.1016/j.drudis.2024.104186","DOIUrl":"10.1016/j.drudis.2024.104186","url":null,"abstract":"<div><div>The use of proteomics in human studies investigating stroke and myocardial infarction (MI) has been increasing, prompting a review of the literature. This revealed proteinaceous biomarkers of stroke from thrombi, brain tissue, cells, and particles, some of which cross the blood–brain barrier (BBB). Several proteins were also implicated in coronary artery disease (CAD), which often underlies MI, cholesterol transportation, and inflammation. Furthermore, the platelet proteome revealed itself as a potential therapeutic target, along with differentially expressed proteins associated with MI progression. Moreover, proteomic data enhanced the performance of conventional risk scores and causal protein discovery has improved interventions and drug development for patients with MI and other conditions. These findings suggest that proteomics holds much promise for future stroke and MI research.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104186"},"PeriodicalIF":6.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early career researchers’ experiences in drug discovery in Africa 非洲早期职业研究人员在药物研发方面的经验。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-18 DOI: 10.1016/j.drudis.2024.104183
Godfrey Mayoka, Peter Mubanga Cheuka
{"title":"Early career researchers’ experiences in drug discovery in Africa","authors":"Godfrey Mayoka,&nbsp;Peter Mubanga Cheuka","doi":"10.1016/j.drudis.2024.104183","DOIUrl":"10.1016/j.drudis.2024.104183","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104183"},"PeriodicalIF":6.5,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the potential of molecular imprinting polymer-based composites in the discovery of advanced drug delivery carriers 揭示分子印迹聚合物基复合材料在发现先进药物输送载体方面的潜力。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-16 DOI: 10.1016/j.drudis.2024.104164
Amit Kumar , Shashi Kashyap , Farhan Mazahir , Rajeev Sharma , Awesh K. Yadav
{"title":"Unveiling the potential of molecular imprinting polymer-based composites in the discovery of advanced drug delivery carriers","authors":"Amit Kumar ,&nbsp;Shashi Kashyap ,&nbsp;Farhan Mazahir ,&nbsp;Rajeev Sharma ,&nbsp;Awesh K. Yadav","doi":"10.1016/j.drudis.2024.104164","DOIUrl":"10.1016/j.drudis.2024.104164","url":null,"abstract":"<div><div>Molecularly imprinted polymers (MIPs) are polymeric matrices that can mimic natural recognition entities, such as antibodies and biological receptors. Molecular imprinting of therapeutics is very appealing in the design of drug delivery systems since the specific and selective binding sites created within the polymeric matrix turn these complex structures into value-added carriers with tunable features, notably high drug-loading capacity and good control of payload release. MIPs possess considerable promise as synthetic recognition elements in ‘theranostics’. Moreover, the high affinity and specificity of MIPs make them more advantageous than other polymer-based nanocomposites. This review summarizes the present state-of-the-art of MIP-based delivery systems for the targeted delivery of bioactives, with current challenges and future perspectives.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104164"},"PeriodicalIF":6.5,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The regulatory mechanism of natural polysaccharides in type 2 diabetes mellitus treatment 天然多糖在 2 型糖尿病治疗中的调节机制
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-09-14 DOI: 10.1016/j.drudis.2024.104182
Surina Bo , Mu Dan , Wei Li , Chen Chen
{"title":"The regulatory mechanism of natural polysaccharides in type 2 diabetes mellitus treatment","authors":"Surina Bo ,&nbsp;Mu Dan ,&nbsp;Wei Li ,&nbsp;Chen Chen","doi":"10.1016/j.drudis.2024.104182","DOIUrl":"10.1016/j.drudis.2024.104182","url":null,"abstract":"<div><div>Diabetes is a complex, multifactorial disease that is caused by a pathological combination of insulin resistance and pancreatic islet dysfunction. Polysaccharides are extensively dispersed in nature and have a very complicated structure with various biological properties. Natural polysaccharides have potentially extraordinary beneficial health effects on managing metabolic diseases such as diabetes, obesity and cardiovascular disease. Thus, a systematic review of the latest research into and possible regulatory mechanisms of natural polysaccharides for type 2 diabetes mellitus treatment is of great significance for a better understanding of their pharmaceutical value. We discuss the regulatory mechanisms of natural polysaccharides for the treatment of diabetes, and especially their role in reshaping dysfunctional gut microbiota. Natural polysaccharides could be developed as new and safe antidiabetic drugs, and detailed mechanistic studies could further clarify the molecular targets of polysaccharides in the treatment of diabetes.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104182"},"PeriodicalIF":6.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624003076/pdfft?md5=0e0518270b681b81f1885e4f5c0b10f9&pid=1-s2.0-S1359644624003076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142258637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信